CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Gral Escobedo, Mexico

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • Clinical Outcomes of Robotic Myomectomy

    Uterine myoma is the most common gynecological tumor. Current surgical management was inclusive of conventional abdominal myomectomy, laparoscopy-assisted myomectomy, robotic-assisted myomectomy. The aim of this study was to identify the predictors of perioperative outcomes in women who receive robotic myomectomy

    Phase

    N/A

    Span

    58 weeks

    Sponsor

    Far Eastern Memorial Hospital

    Banqiao, New Taipei

    Recruiting

  • Gravity Versus Pump Infusion of Distending Media for Hysteroscopic Myomectomy

    Phase

    N/A

    Span

    58 weeks

    Sponsor

    Far Eastern Memorial Hospital

    Banqiao, New Taipei

    Recruiting

  • Therapeutic Efficacy in Women With Stress Urinary Incontinence

    Background/Purpose: Pharmacologic treatments for female stress urinary incontinence (SUI) include duloxetine and imipramine. Duloxetine and Imipramine has been reported to have clinical significant therapeutic efficacy on female SUI and overactive bladder syndrome. However, there was no randomized controlled study to compare duloxetine and imipramine for the treatment of female SUI. Patients and Methods: We will perform a prospective randomized controlled study to recruit 90 female SUI patients at the Obstetrics & Gynecology outpatient clinic of Far Eastern Memorial Hospital. All SUI female patients will be asked to complete ICIQ-UI, USS, OABSS, and bladder diary before and after 4 weeks' duloxetine versus imipramine treatment.

    Phase

    3

    Span

    89 weeks

    Sponsor

    Far Eastern Memorial Hospital

    Banqiao, New Taipei

    Recruiting

  • Comparison of Prognosis in Endometrial Cancer Treated With Different Surgical Methods: Laparoscopy, Robotic-assisted Laparoscopy and Laparotomy

    We will review the medical records of clinically uterine-confined endometrial cancer women who received robotic-assisted laparoscopic, laparoscopic or laparotomic methods; and compare their outcomes.

    Phase

    N/A

    Span

    78 weeks

    Sponsor

    Far Eastern Memorial Hospital

    Banqiao, New Taipei

    Recruiting

  • Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled Study

    Patients and methods: We will conduct a prospective randomized controlled study in the outpatient clinic of Department of Obstetrics and Gynecology of Far Eastern Memorial Hospital, and will recruit 150 female patients with overactive bladder syndrome. All female patients with overactive bladder syndrome enrolled in the study will be requested to fill in the urgency severity score, the overactive bladder symptom score questionnaire, and the King's health questionnaire before taking the drug and four weeks and twelve weeks after taking the drug. In addition, measurement of heart rate variability and bladder blood perfusion will be performed. Expected results: We will obtain the impact of monotherapy with tolterodine or mirabegron versus combined therapy on heart rate variability and bladder blood perfusion in women with overactive bladder syndrome.

    Phase

    4

    Span

    47 weeks

    Sponsor

    Far Eastern Memorial Hospital

    Banqiao, New Taipei

    Recruiting

  • Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin

    To assess the impact of mirabegron versus solifenacin on psychological distress, sexual function, bladder wall thickness and blood flow.

    Phase

    3

    Span

    283 weeks

    Sponsor

    Far Eastern Memorial Hospital

    Banqiao, New Taipei

    Recruiting

  • Clinical Effectiveness of First Trimester Pre-eclampsia Screening Program.

    The incidence of pre-eclampsia is about 2-8%, it is a leading cause of maternal and perinatal mortality and morbidity. Both ACOG (American Congress of Obstetricians and Gynecologists) and NICE (National Institute for Health and Clinical Excellence) guideline advocate the use of traditional screening method, which uses demographic characters and medical history to identify high risk women. This method detects only 35-40% of pre-eclampsia women. Study has shown that combination of maternal factors and biomarkers (uterine artery pulsatility index, placenta growth factor, PlGF; pregnancy associated plasma protein-A, PAPP-A) improves the detection rate. In Taiwan, the prevalence of pre-eclampsia is about 1.21%. The incidence of pre-eclampsia is correlated with maternal age, with a relative risk of 5.13-fold in women aged 40 and above. Marrying late predisposes these women at high risk of developing pre-eclampsia. Our institution will be implementing first-trimester screening program starting from April 2019, this study aims to evaluate the clinical effectiveness of this screening program in preventing pre-eclampsia.

    Phase

    N/A

    Span

    315 weeks

    Sponsor

    Far Eastern Memorial Hospital

    Banqiao, New Taipei

    Recruiting

  • Impact of Female Pelvic Reconstruction Surgery on Lower Urinary Tract Symptoms, Psychosomatic Distress and Sexual Function

    Phase

    N/A

    Span

    240 weeks

    Sponsor

    Far Eastern Memorial Hospital

    Banqiao, New Taipei

    Recruiting

  • The Role of Endometrial Blood Flow in Endometrial Cancer

    Phase

    N/A

    Span

    469 weeks

    Sponsor

    Far Eastern Memorial Hospital

    Banqiao, New Taipei

    Recruiting

  • Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

    Phase

    N/A

    Span

    192 weeks

    Sponsor

    Far Eastern Memorial Hospital

    Banqiao, New Taipei

    Recruiting

1-10 of 19
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information